Once Upon a Farm, PBC
No enriched coverage for $OFRM in the last 7 days.
Once Upon A Farm (OFRM) reported Q2 FY2026 net sales of $85.4 million, up 42.3% year over year on a 40.3% volume increase. Management raised full-year net sales guidance to $327 million to $335 million and adjusted EBITDA to $3.0 million to $4.5 million. Gross margin was 35.9% and the company had a $5.0 million net loss.
Once Upon a Farm (NYSE:OFRM) reported Q2 growth, with baby sales up 73% to $41.5M and kid sales up 22% to $43.9M, alongside distribution point expansion. Gross margin fell to 35.9% (down 485 bps). SG&A rose to $36.3M. Net loss was $5M. The company cut FY gross margin outlook to ~40% and expects Q3 similar margins.
Once Upon a Farm (NYSE: OFRM) reported Q2 2026 net sales up more than 42% year over year to $85.4 million, beating expectations, and raised full-year revenue guidance for a second straight quarter. The company now forecasts 2026 net sales of $325 million to $335 million, citing continued distribution expansion and growth in baby and kids categories.
Recent OFRM coverage spans earnings and financial news.
In the last 30 days, OFRM insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($36K). The most active reporter was Curtis Cassandra Nicole, Chief Innovation Officer, with 1 filing.
Raised revenue and adjusted EBITDA guidance alongside margin pressure and tariff/sourcing risk management.
Guidance cut plus margin pressure from mix, trade spending, and fuel/tariffs likely keeps near-term sentiment cautious despite distribution and price actions.
Guidance lift plus strong Q2 growth suggests improving demand and distribution momentum, supporting bullish near-term positioning.
Raised full-year outlook alongside improving losses and cash position, signaling stronger demand and operating leverage but with margin pressure.
OFRM shows a neutral sentiment with low relevance to broader market movements. Its slight positive sentiment suggests limited immediate trading impact.
alphai scores every news story that mentions OFRM with an AI model for sentiment and relevance, and aggregates insider trades from Once Upon a Farm, PBC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Once Upon A Farm (OFRM) reported Q2 FY2026 net sales of $85.4 million, up 42.3% year over year on a 40.3% volume increase. Management raised full-year net sales guidance to $327 million to $335 million and adjusted EBITDA to $3.0 million to $4.5 million. Gross margin was 35.9% and the company had a $5.0 million net loss.
7 min readOnce Upon a Farm (NYSE:OFRM) reported Q2 growth, with baby sales up 73% to $41.5M and kid sales up 22% to $43.9M, alongside distribution point expansion. Gross margin fell to 35.9% (down 485 bps). SG&A rose to $36.3M. Net loss was $5M. The company cut FY gross margin outlook to ~40% and expects Q3 similar margins.
4 min readOnce Upon a Farm (NYSE: OFRM) reported Q2 2026 net sales up more than 42% year over year to $85.4 million, beating expectations, and raised full-year revenue guidance for a second straight quarter. The company now forecasts 2026 net sales of $325 million to $335 million, citing continued distribution expansion and growth in baby and kids categories.
4 min readOnce Upon a Farm, PBC (OFRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Once Upon a Farm Reports Second Quarter 2026 Financial Results Second quarter net sales increased 42% year-over-year to $85 million Raising 2026 net sales outlook to $327 million to $335 million Raising 2026 Adjusted EBITDA outlook to $3 million to $4.5 million BERKELEY, Calif.,
7 min readOnce Upon a Farm has launched a significant expansion of its product portfolio, introducing new nutrient-dense pouches for children. These new offerings include options like Meat, Meat & Bone Broth, Legume Blends, and Smoothies with Protein & Probiotics, catering to different developmental stages from infants to active kids. The expansion aims to meet parental demand for convenient, organic, and farm-fresh nutrition, moving into refrigerated protein-forward formats.
3 min readStifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.
4 min read
